Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vildagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 17/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vildagliptin SCHEMBL27193113 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL10031674 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665401 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16155482 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16579 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665400 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL354910 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118948849-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-11-15 | — | — | CN | claimed |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-11-14 | — | — | US | claimed |
| EP-4400105-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | Shionogi & Co., Ltd (JP) | 2024-07-17 | — | — | EP | claimed |
| CN-118215478-A | Medicine for preventing and treating diseases related to anti-obesity effect | 盐野义制药株式会社 | 2024-06-18 | — | — | CN | claimed |
| WO-2023038039-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | 塩野義製薬株式会社 | 2023-03-16 | — | — | WO | claimed |
| US-20260097037-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | SHIONOGI & CO., LTD. (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260076972-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | disclosed |
| EP-4592285-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | Shionogi & Co., Ltd. (JP) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025127097-A1 | MEDICINE FOR TREATING STEATOTIC LIVER DISEASES | 塩野義製薬株式会社 | 2025-06-19 | — | — | WO | disclosed |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| CN-119907794-A | Fused ring compounds having GLP-1 receptor agonist action | 盐野义制药株式会社 | 2025-04-29 | — | — | CN | disclosed |
| CN-107961377-B | Combination therapy | 勃林格殷格翰国际有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115300472-A | Pharmaceutical composition and preparation method thereof | 杭州民生药物研究院有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220340575-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | BOEHRINGER INGELHEIM INT (DE) | 2022-10-27 | — | — | US | disclosed |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2022-10-13 | — | — | US | disclosed |
| US-20220226283-A1 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND DPP-4 INHIBITOR | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2022-07-21 | — | — | US | disclosed |
| EP-4014998-A1 | COMBINATION PRODUCT COMPRISING LIMONOID AND DPP-4 INHIBITORS | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2022-06-22 | — | — | EP | disclosed |
| US-20220088023-A1 | ANTIDIABETIC MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2022-03-24 | — | — | US | disclosed |
| WO-2022023213-A1 | PHARMACEUTICAL FORMULATION OF METFORMIN HAVING LOW CONTENT OF DIMETHYLAMINE | KRKA, D. D., NOVO MESTO (SI) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340575-A1 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 99/4885DPP8 5/4885 |
| US-20220088023-A1 | ANTIDIABETIC MEDICATIONS | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885FAP 1562/4885DPP8 14/4885 |
| US-20220226283-A1 | COMBINATION PRODUCT CONTAINING LIMONOID COMPOUND AND DPP-4 INHIBITOR | DPP4, DPP3, DPP9 | DPP4 1/4885FAP 64/4885DPP8 5/4885 |
| US-20260097037-A1 | FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, CCKAR, GCGR | DPP4 262/4885FAP 3072/4885DPP8 198/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885DPP8 5/4885 |
| US-12312352-B2 | Use of a DPP-4 inhibitor in SIRS and/or sepsis | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 99/4885DPP8 5/4885 |
| US-20240374587-A1 | MEDICINE FOR PREVENTION AND TREATMENT OF DISEASES LINKED TO ANTI-OBESITY ACTIVITY | PNLIP, LIPC, GPR119 | DPP4 95/4885FAP 2944/4885DPP8 178/4885 |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885DPP8 5/4885 |
| US-20260076972-A1 | ANTIDIABETIC MEDICATIONS | IAPP, DPP4, PYGL | DPP4 2/4885FAP 863/4885DPP8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.